Halozyme Therapeutics, Inc.

HALO14 Dec 2024
Healthcare
$47.81
+0.00 (+0.38%)
Lowest Today
$47.53
Highest Today
$48.31
Today’s Open
$47.81
Prev. Close
$47.83
52 Week High
$65.53
52 Week Low
$33.15
To Invest in Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc.

Healthcare
HALO14 Dec 2024
+0.00 (+0.38%)
1M
3M
6M
1Y
5Y
Low
$47.52
Day’s Range
High
$48.31
47.52
52 Week Low
$33.15
52-Week Range
52 Week High
$65.53
33.15
1 Day
-
1 Week
-1.15%
1 month return
-18.46%
3 month return
-23.25%
6 month return
-3.56%
1 Year return
+13.58%
3 Years return
+37.99%
5 Years return
+152.2%
10 Years return
-
Institutional Holdings
BlackRock Inc
13.85
Vanguard Group Inc
10.14
State Street Corp
5.21
iShares Core S&P Mid-Cap ETF
3.2
Snyder Capital Management LP
3.19
Vanguard Total Stock Mkt Idx Inv
3.16
iShares Russell 2000 ETF
2.74

Market Status

Fundamentals
Market Cap
6029.29 mln
PB Ratio
13.32
PE Ratio
15.69
Enterprise Value
6867.14 mln
Total Assets
1733.27 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
Organisation
Halozyme Therapeutics, Inc.
Employees
373
Industry
Biotechnology
CEO
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step